Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the following conferences:
- Keystone Symposia on Precision Genome Engineering: Translating the Human Genome to the Clinic: Jason Fernandes, Principal Scientist at Scribe, will present a late-breaking talk titled "Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates" on Tuesday, March 4, 2025 between 3:00-4:30 p.m. GMT in Killarney, Ireland. The Symposia Spotlight presentation will showcase the latest developments in Epigenetic Long-Term X-Repressors (ELXRs), Scribe's proprietary epigenetic editing technology. The talk will feature data supporting a holistic engineering approach to developing potent ELXRs and unveil a novel class of repressive domains that enhance the activity of epigenetic editors, thereby broadening their therapeutic window.
- Leerink Partners Global Healthcare Conference: Scribe co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will be available for one-on-one meetings with investors on Tuesday, March 11, 2025 in Miami, FL.
About Scribe Therapeutics
Scribe Therapeutics is revolutionizing medicine by developing optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. The company is on a mission to build the first CRISPR-based therapeutics that are effective and safe enough to transform everyone's lifetime risk for disease. Scribe's CRISPR by Design approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity, and deliverability, enabling the creation of therapies with a broader therapeutic window and safe for use as a preventative treatment. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225754123/en/
Contacts:
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
